Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials

医学 妥珠单抗 银屑病性关节炎 内科学 类风湿性关节炎 不利影响 银屑病 人口 入射(几何) 皮肤病科 狼牙棒 依那西普 传统PCI 心肌梗塞 物理 环境卫生 光学
作者
Jeffrey R. Curtis,Xavier Mariette,Cécile Gaujoux-Viala,Andrew Blauvelt,Tore Kristian Kvien,William J. Sandborn,Kevin L. Winthrop,Marc De Longueville,I. Huybrechts,Vivian P. Bykerk
出处
期刊:RMD Open [BMJ]
卷期号:5 (1): e000942-e000942 被引量:71
标识
DOI:10.1136/rmdopen-2019-000942
摘要

Objective: To review long-term certolizumab pegol (CZP) safety across all approved indications: rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis (PSO) and Crohn's disease (CD). Methods: Data were pooled across 49 UCB-sponsored CZP clinical trials (27 RA, one axSpA, one PsA, five PSO, 15 CD) to August 2017. Serious adverse events (SAEs) of interest (infections, malignancies, autoimmunity/hypersensitivity events, major adverse cardiovascular events (MACE), gastrointestinal (GI) perforations, psoriasis events, laboratory abnormalities) and deaths were medically reviewed by an external expert committee, using predefined case rules. Incidence rates (IRs)/100 patient-years (PY) are presented by indication; standardised mortality and malignancy rates were calculated using WHO/GLOBOCAN/SEER databases. Pregnancies with maternal CZP exposure are also reported. Results: Of 11 317 CZP-treated patients across indications (21 695 PY CZP exposure; maximum: 7.8 years), infections were the most common SAEs (overall IR: 3.62/100 PY; IRs ranged from 1.50/100 PY(PSO) to 5.97/100 PY(CD)). The IR for malignancies was 0.82/100 PY, including lymphoma (0.06/100 PY). MACE and GI perforation IRs in CZP-treated patients were 0.47/100 PY and 0.08/100 PY and were highest in RA and CD, respectively. Patients with PSO had the lowest SAE rates. The incidence of deaths and malignancies aligned with expected general population data. Conclusion: This extensive overview of the CZP safety profile in clinical trials, across all indications, provides large-scale confirmation of previous reports. No new safety signals or relevant non-disease-related laboratory abnormalities were identified. The study demonstrated some indication-specific differences in certain SAE rates that may be attributable to the underlying inflammatory disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
momo完成签到,获得积分10
刚刚
刚刚
Maestro_S的应助被Zhou采纳,获得10
1秒前
1秒前
科研通AI6.3的应助被魏伯安采纳,获得10
2秒前
2秒前
2秒前
3秒前
4秒前
5秒前
一抹火烧云完成签到,获得积分10
5秒前
深情安青的应助被奔跑少年采纳,获得10
5秒前
欢喜灵13发布了新的文献求助10
6秒前
感谢大家发布了新的文献求助10
6秒前
动听海秋发布了新的文献求助10
6秒前
7秒前
汉堡包的应助被美满乐荷采纳,获得10
7秒前
无极微光的应助被Yutong采纳,获得50
7秒前
风吹麦浪发布了新的文献求助10
7秒前
7秒前
7秒前
搜集达人的应助被QUPY采纳,获得10
7秒前
沉默小玉完成签到,获得积分10
8秒前
fanjia完成签到,获得积分10
8秒前
田乐天完成签到 ,获得积分10
8秒前
知性的沂完成签到,获得积分10
8秒前
伶俐子默发布了新的文献求助10
9秒前
万能图书馆的应助被sincerely采纳,获得10
9秒前
9秒前
9秒前
10秒前
11秒前
阿呸完成签到,获得积分10
11秒前
yuxyu完成签到 ,获得积分10
11秒前
huhuhaoshuai发布了新的文献求助10
11秒前
11秒前
11秒前
杪春发布了新的文献求助10
12秒前
林读书发布了新的文献求助10
12秒前
阿杳完成签到 ,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181949
求助须知:如何正确求助?哪些是违规求助? 9571702
关于积分的说明 21819272
捐赠科研通 7778399
什么是DOI,文献DOI怎么找? 3433572
关于科研通互助平台的介绍 2557769
邀请新用户注册赠送积分活动 2479630